Tags » Chronic Lymphocytic Leukemia

Dr. Richard Furman Examines Future of CLL Risk Assessment

At OncLive’s State of the Science Summit on Hematologic Malignancies, Dr. Richard Furman, director of the Chronic Lymphocytic Leukemia (CLL) Research Center at Weill Cornell Medicine, discussed how medical oncologists should be using prognostic markers to make risk assessments in order to determine individualized treatments for their patients with CLL. 385 more words

Patient Education

My Journey

It has been more than nine months since I wrote anything on my blog. I have not written, because I have not needed to see my Oncologist since last April 2016. 546 more words


FAT1 Mutations Influence Time to First Treatment in Untreated CLL

By John Allan, M.D.

Despite recent strides in mapping the mutational landscape of chronic lymphocytic leukemia (CLL) there is still limited information regarding the clinical impact of some less common gene mutations in the treatment of CLL. 272 more words

Patient Education

NICE takes Imbruvica off the CDF, available routinely against chronic lymphocytic leukaemia

Hundreds of people could benefit as NICE decision means ibrutinib can come off the Cancer Drugs Fund (CDF) and be routinely available to treat chronic lymphocytic leukaemia. 197 more words


Six Weeks on Ibrutinib = Minor Side Effects

So in general, I feel fine. I don’t notice that I feel any better than I did before I started Ibrutinib. Nor do I notice that I feel any worse. 400 more words